Valuation: AbbVie Inc.

Market Cap 501B 456B 421B 383B 718B 46,410B 754B 5,119B 2,035B 25,349B 1,880B 1,841B 79,556B P/E 2026 *
36.1x
P/E 2027 * 26.6x
Enterprise Value 564B 514B 474B 431B 808B 52,265B 850B 5,765B 2,291B 28,547B 2,118B 2,073B 89,592B EV / Sales 2026 *
8.33x
EV / Sales 2027 * 7.5x
Free-Float
95.64%
Yield 2026 *
2.43%
Yield 2027 * 2.56%
1 day+1.86%
1 week-2.09%
Current month-2.04%
1 month-0.07%
3 months+10.33%
6 months+36.07%
Current year+26.43%
1 week 279.88
Extreme 279.88
301.2
1 month 278.01
Extreme 278.01
302.93
Current year 190.75
Extreme 190.75
302.93
1 year 190.75
Extreme 190.75
302.93
3 years 137.65
Extreme 137.65
302.93
5 years 115.01
Extreme 115.01
302.93
10 years 58.6
Extreme 58.6
302.93
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

59 0.0000%
30/09/26 Free

Director

129 0.0000%
14/08/26 Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-2.09%+25.90%+108.86% 501B
-0.02%-6.34%+29.59%+126.24% 1,204B
+1.75%-4.83%+33.92%+81.42% 643B
-0.60%-1.95%+27.26%+67.32% 378B
+1.28%-8.76%+41.96%+31.30% 327B
+0.41%-4.70%+27.23%+51.59% 285B
+0.81%-4.08%-1.74%+32.71% 270B
+0.17%-6.04%+30.19%+64.89% 237B
+0.80%-0.02%+34.45%+121.12% 207B
-0.25%-5.01%-15.80%-62.38% 172B
Average +0.61%-4.35%+23.30%+62.31% 422B
Weighted average by Cap. +0.64%-4.67%+26.82%+82.34%

Financials

2026 *2027 *
Net sales 67.79B 61.75B 56.9B 51.75B 97.09B 6,278B 102B 692B 275B 3,429B 254B 249B 10,761B 74.02B 67.42B 62.12B 56.51B 106B 6,854B 111B 756B 301B 3,744B 278B 272B 11,750B
Net income 14.35B 13.07B 12.04B 10.96B 20.55B 1,329B 21.6B 147B 58.26B 726B 53.84B 52.71B 2,278B 19.32B 17.59B 16.21B 14.75B 27.67B 1,789B 29.08B 197B 78.43B 977B 72.48B 70.95B 3,066B
Net Debt 63.23B 57.59B 53.06B 48.27B 90.55B 5,855B 95.17B 646B 257B 3,198B 237B 232B 10,036B 54.29B 49.45B 45.56B 41.44B 77.75B 5,027B 81.71B 555B 220B 2,746B 204B 199B 8,617B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
20/11/26 $288.85 +1.87% 2,892,019
19/11/26 $283.54 -0.86% 5,047,453
18/11/26 $286.01 -2.33% 4,842,258
17/11/26 $292.82 -0.59% 3,950,014
16/11/26 $294.55 -0.16% 5,493,798
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
283.54USD
Average target price
315.88USD
Spread / Average Target
+11.41%
  1. Stock Market
  2. Stocks
  3. ABBV Stock